Biophytis S.A. (0D1W.L)

0,0024 -0,0001 (-4,00%) Alla chiusura: 04:01PM BST

Biophytis S.A.

Sorbonne University
BC 9, BAtiment A 4Eme Etage 4 place Jussieu Cedex 05
Paris 75005
France
33 1 44 27 23 00
https://www.biophytis.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 22

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Stanislas Veillet Ph.D.	Chairman of the Board & CEO	349k	N/D	1965
Mr. Nicolas Fellmann	Chief Financial Officer	N/D	N/D	1968
Mr. Waly Dioh Ph.D.	Chief Clinical Operating Officer	N/D	N/D	1969
Dr. Pierre J. Dilda Ph.D.	Chief Scientific Officer	N/D	N/D	1970
Dr. Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	N/D	N/D	1946
Dr. Rob van Maanen FFPM, M.B.A., M.D.	Chief Medical Officer	N/D	N/D	1971
Mr. Edouard Bieth	Chief Business Officer	N/D	N/D	1980
Ms. Chiara Baccelli	Chief Pharmaceutical Operations Officer & Quality Assurance Director	N/D	N/D	N/D
Ms. _ Teylan	Financial Controller	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Governance aziendale

L'ISS Governance QualityScore di Biophytis S.A. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.